A multivariate analysis of patients with brain tumors treated with ATN-RNA.
Glioblastoma multiforme (GBM) is the most common form of malignant glioma, characterized by genetic instability, intratumoral histopathological variability, and unpredictable clinical behavior. Malignant gliomas express preferentially a number of surface markers that may be exploited as therapeutic targets, such as tenascin-C, an extracellular matrix glycoprotein contributes to tumor cell adhesion, invasion, migration and proliferation. Disappointing results in the treatment of gliomas with surgery, radiation and chemotherapy have fuelled a search for new treatment modalities. Here we present the data for 46 patients suffering from brain tumor. They were resected and treated with dsRNA (ATN-RNA) complementary to the sequence of tenascin-C mRNA. MRI and CT follow up studies showed growth tumor delay or lack of its recurrence symptoms, due to inhibition of TN-C synthesis. A significant improvement in overall survival (OS) was observed without loosing of the quality of life (QOL) of patients. This novel therapy based on RNA interference shows a big therapeutical potential. To our knowledge intervention with RNAi (iRNAi) is the first protocol of application of RNAi in human disease treatment.
Wyszko
Eliza
E
Institute of Bioorganic Chemistry of the Polish Academy of Sciences, 12 Noskowskiego St., 61-704 Poznań, Poland.
Rolle
Katarzyna
K
Nowak
Stanislaw
S
Zukiel
Ryszard
R
Nowak
Monika
M
Piestrzeniewicz
Rafał
R
Gawrońska
Iwona
I
Barciszewska
Mirosława Z
MZ
Barciszewski
Jan
J
D000328:Adult; D000368:Aged; D001483:Base Sequence; D001932:Brain Neoplasms / Q000503:physiopathology / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D005909:Glioblastoma / Q000503:physiopathology / Q000628:therapy; D005910:Glioma / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009364:Neoplasm Recurrence, Local; D011788:Quality of Life; D034622:RNA Interference; D012330:RNA, Double-Stranded / Q000627:therapeutic use*; D012333:RNA, Messenger / Q000378:metabolism; D015996:Survival Rate; D019063:Tenascin / Q000235:genetics / Q000378:metabolism*; D014057:Tomography, X-Ray Computed; D055815:Young Adult
D012330:RNA, Double-Stranded; D012333:RNA, Messenger; D019063:Tenascin